Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):611–620. doi: 10.1054/bjoc.2000.1669

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

Meta-Analysis Group in Cancer
PMCID: PMC2363786  PMID: 11237380

Abstract

Two meta-analyses were conducted to quantify the benefit of combining α-IFN to 5FU in advanced colorectal cancer in terms of tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial. The meta-analysis of 5FU ± LV vs. 5FU ± LV + α-IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for patients receiving no α-IFN vs. 24% for patients receiving α-IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients receiving no α-IFN vs. 11.5 months for patients receiving α-IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + α-IFN combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + α-IFN which was statistically significant in terms of tumour response (23% vs. 18%; RR = 1.26;P = 0.042), and of a borderline significance for overall survival (HR = 1.11;P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response, whereas good performance status, metastases confined to the liver or confined to the lung, and primary tumour in the rectum were independent favourable prognostic factors for survival. We conclude that α-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + α-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: 5-fluorouracil, interferon, colorectal cancer, meta-analysis

Full Text

The Full Text of this article is available as a PDF (99.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colucci G., Maiello E., Gebbia V., Giuliani F., Serravezza G., Lelli G., Leo S., Filippelli G., Nicolella G., Brandi M. 5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group. Cancer. 1999 Feb 1;85(3):535–545. [PubMed] [Google Scholar]
  2. Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 Mar 25;355(9209):1041–1047. doi: 10.1016/s0140-6736(00)02034-1. [DOI] [PubMed] [Google Scholar]
  3. Dufour P., Husseini F., Dreyfus B., Cure H., Martin C., Prevost G., Olivier J. P., Dumas F., Duclos B., Olivares R. 5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study. Ann Oncol. 1996 Aug;7(6):575–579. doi: 10.1093/oxfordjournals.annonc.a010673. [DOI] [PubMed] [Google Scholar]
  4. Elias L., Crissman H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 1988 Sep 1;48(17):4868–4873. [PubMed] [Google Scholar]
  5. Greco F. A., Figlin R., York M., Einhorn L., Schilsky R., Marshall E. M., Buys S. S., Froimtchuk M. J., Schuller J., Schuchter L. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996 Oct;14(10):2674–2681. doi: 10.1200/JCO.1996.14.10.2674. [DOI] [PubMed] [Google Scholar]
  6. Hill M., Norman A., Cunningham D., Findlay M., Nicolson V., Hill A., Iveson A., Evans C., Joffe J., Nicolson M. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995 Jun;13(6):1297–1302. doi: 10.1200/JCO.1995.13.6.1297. [DOI] [PubMed] [Google Scholar]
  7. Hill M., Norman A., Cunningham D., Findlay M., Watson M., Nicolson V., Webb A., Middleton G., Ahmed F., Hickish T. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol. 1995 Sep;13(9):2317–2323. doi: 10.1200/JCO.1995.13.9.2317. [DOI] [PubMed] [Google Scholar]
  8. Kosmidis P. A., Tsavaris N., Skarlos D., Theocharis D., Samantas E., Pavlidis N., Briassoulis E., Fountzilas G. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol. 1996 Oct;14(10):2682–2687. doi: 10.1200/JCO.1996.14.10.2682. [DOI] [PubMed] [Google Scholar]
  9. Köhne C. H., Schöffski P., Wilke H., Käufer C., Andreesen R., Ohl U., Klaasen U., Westerhausen M., Hiddemann W., Schott G. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol. 1998 Feb;16(2):418–426. doi: 10.1200/JCO.1998.16.2.418. [DOI] [PubMed] [Google Scholar]
  10. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  11. Neefe J. R., John W. Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin Oncol. 1991 Oct;18(5 Suppl 7):77–82. [PubMed] [Google Scholar]
  12. Palmeri S., Meli M., Danova M., Bernardo G., Leonardi V., Dastoli G., Rausa L., Russo A., Filippelli G., Palmieri G. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol. 1998;124(3-4):191–198. doi: 10.1007/s004320050154. [DOI] [PubMed] [Google Scholar]
  13. Pazdur R., Ajani J. A., Patt Y. Z., Winn R., Jackson D., Shepard B., DuBrow R., Campos L., Quaraishi M., Faintuch J. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990 Dec;8(12):2027–2031. doi: 10.1200/JCO.1990.8.12.2027. [DOI] [PubMed] [Google Scholar]
  14. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Piga A., Cascinu S., Latini L., Marcellini M., Bavosi M., Acito L., Bascioni R., Giustini L., Francini G., Pancotti A. A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. Br J Cancer. 1996 Sep;74(6):971–974. doi: 10.1038/bjc.1996.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Raderer M., Scheithauer W. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. Eur J Cancer. 1995 Jun;31A(6):1002–1008. doi: 10.1016/0959-8049(95)00078-x. [DOI] [PubMed] [Google Scholar]
  17. Recchia F., Nuzzo A., Lalli A., Lombardo M., Di Lullo L., Fabiani F., Fanini R., Venturoni L., Torchio P., Peretti G. Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. Am J Clin Oncol. 1996 Jun;19(3):301–304. doi: 10.1097/00000421-199606000-00019. [DOI] [PubMed] [Google Scholar]
  18. Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 Sep 28;343(13):905–914. doi: 10.1056/NEJM200009283431302. [DOI] [PubMed] [Google Scholar]
  19. Seymour M. T., Slevin M. L., Kerr D. J., Cunningham D., James R. D., Ledermann J. A., Perren T. J., McAdam W. A., Harper P. G., Neoptolemos J. P. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol. 1996 Aug;14(8):2280–2288. doi: 10.1200/JCO.1996.14.8.2280. [DOI] [PubMed] [Google Scholar]
  20. Villar-Grimalt A., Candel M. T., Massuti B., Lizón J., Sánchez B., Frau A., Gorostidi B., Goedkoop R. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer. Br J Cancer. 1999 May;80(5-6):786–791. doi: 10.1038/sj.bjc.6690422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wadler S., Schwartz E. L., Goldman M., Lyver A., Rader M., Zimmerman M., Itri L., Weinberg V., Wiernik P. H. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989 Dec;7(12):1769–1775. doi: 10.1200/JCO.1989.7.12.1769. [DOI] [PubMed] [Google Scholar]
  22. Weh H. J., Platz D., Braumann D., Buggisch P., Schmiegel W. H., Drescher S., Kleeberg U. R., Müllerleile U., Crone-Münzebrock W., Hoffman R. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study. Semin Oncol. 1992 Apr;19(2 Suppl 3):180–184. [PubMed] [Google Scholar]
  23. Wolmark N., Bryant J., Smith R., Grem J., Allegra C., Hyams D., Atkins J., Dimitrov N., Oishi R., Prager D. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998 Dec 2;90(23):1810–1816. doi: 10.1093/jnci/90.23.1810. [DOI] [PubMed] [Google Scholar]
  24. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938–2947. doi: 10.1200/JCO.2000.18.16.2938. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES